Gilead Sciences, Inc. $GILD Shares Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 428,912 shares of the biopharmaceutical company’s stock after selling 21,232 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $47,719,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. GoalVest Advisory LLC grew its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences during the 3rd quarter valued at $26,000. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at $27,000. Putney Financial Group LLC boosted its position in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. Finally, Howard Hughes Medical Institute acquired a new stake in Gilead Sciences in the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $70,740,911.34. The trade was a 1.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 141,757 shares of company stock worth $17,569,112. 0.27% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent research reports. Needham & Company LLC boosted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Royal Bank Of Canada boosted their price target on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research report on Tuesday. HSBC increased their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Finally, Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.52.

Gilead Sciences Price Performance

GILD stock opened at $135.93 on Friday. The stock’s 50 day moving average is $123.98 and its two-hundred day moving average is $118.62. Gilead Sciences, Inc. has a 52-week low of $92.26 and a 52-week high of $136.30. The company has a market capitalization of $168.65 billion, a PE ratio of 21.07, a P/E/G ratio of 0.69 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.